Glooko raises $30M to accelerate growth

PALO ALTO, Calif. – Glooko, a provider of remote patient monitoring and chronic care management solutions including diabetes and obesity, has raised a $30 million Series D round of funding.  

The company will use proceeds from the funding to accelerate organic growth and strategic initiatives across its product line of digital health solutions, including increasing adoption of is remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional areas. 

"Glooko has done a remarkable job of bringing to market cutting edge digital health care platforms, which empower people with diabetes to better manage their disease and improve their lives,” said Charles Boorady, founder and managing partner of Health Catalyst Capital, which led the financing. “As a result of Glooko’s innovations, the company has experienced rapid market adoption, growing its global ecosystem to more than 7,500 clinics, and has entered into partnerships with many of the world's largest diabetes medical device companies and pharmaceutical companies, as well as top health care systems.” 

The funding follows a successful 2020 for Glooko, its most successful so far, despite the global pandemic. Last year, the company’s growth included key partnerships with major health care systems and extended long-term existing partnerships with several global diabetes companies such as Insulet and Novo Nordisk.  

Others participating in the funding include existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic.